Long-Term Feeding Soy Protein Concentrates Protect Against Hepatic Steatosis Independent of Isoflavone Levels

被引:1
|
作者
Li, Wei [1 ]
Spray, Beverly [4 ]
Borsheim, Elisabet [2 ,4 ,5 ]
Korourian, Soheila [3 ]
Hakkak, Reza [1 ,2 ,4 ]
机构
[1] Univ Arkansas Med Sci, Dept Dietet & Nutr, Mail 627, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA
[3] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[4] Arkansas Childrens Res Inst, Little Rock, AR USA
[5] Arkansas Childrens Nutr Ctr, Little Rock, AR USA
关键词
isoflavone; nonalcoholic fatty liver disease; obesity; soy protein concentrate; FATTY LIVER-DISEASE; UNITED-STATES; ISOLATE; OBESITY; DIET; RISK; RATS;
D O I
10.1089/jmf.2023.0118
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The health benefits of soy foods are attributed to the high-quality protein and the bioactive compounds such as isoflavones. We previously reported that feeding obese (fa/fa) Zucker rats soy protein concentrates (SPCs) with low isoflavone (LIF) and high isoflavone (HIF) for 9 weeks significantly reduced liver steatosis compared to a casein control (C) diet. The current study extended the dietary treatments to 18 weeks to investigate the long-term effect of LIF and HIF SPC diets. 6-week-old male lean (L, n = 21) and obese (O, n = 21) Zucker rats were fed a casein C diet, LIF and HIF SPC diets for 18 weeks and body weight (BW) was recorded twice weekly. Rats were killed after 18 weeks to measure liver steatosis and serum aspartate aminotransferase and alanine aminotransferase. Obese rats had significantly greater final BW, liver weight, liver weight as the percentage of BW, and steatosis score compared to lean rats in all three dietary groups. The obese high-isoflavones (OHIF) group had significantly higher BW compared to obese control (OC) group (P < .0001) and obese low-isoflavones (OLIF) group (P = .01). OC group had significantly greater liver weight, liver weight as the percentage of BW, and liver steatosis score compared to OLIF (P = .0077, P < .0001 and P < .0001, respectively) and OHIF (P = .0094, P < .0001, and P < .0001, respectively) groups. Taken together, long-term feeding of SPC diets protected against liver steatosis regardless of isoflavone levels.
引用
收藏
页码:911 / 918
页数:8
相关论文
共 50 条
  • [31] HELPING PROTECT THE ELDERLY AND THE PUBLIC AGAINST THE CATASTROPHIC COSTS OF LONG-TERM CARE
    JACOBS, B
    WEISSERT, WG
    JOURNAL OF POLICY ANALYSIS AND MANAGEMENT, 1986, 5 (02) : 378 - 383
  • [33] Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel
    Loven, D.
    Levavi, H.
    Sabach, G.
    Zart, R.
    Andras, M.
    Fishman, A.
    Karmon, Y.
    Levi, T.
    Dabby, R.
    Gadoth, N.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (01) : 78 - 83
  • [34] A LONG-TERM METABOLIC STUDY TO ASSESS THE NUTRITIONAL-VALUE OF AND IMMUNOLOGICAL-TOLERANCE TO 2 SOY-PROTEIN CONCENTRATES IN ADULT HUMANS
    BEER, WH
    MURRAY, E
    OH, SH
    PEDERSEN, HE
    WOLFE, RR
    YOUNG, VR
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1989, 50 (05): : 997 - 1007
  • [35] VITAMIN PLASMA-LEVELS IN LONG-TERM ENTERAL FEEDING PATIENTS
    BERNER, Y
    MORSE, R
    FRANK, O
    BAKER, H
    SHIKE, M
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 1989, 13 (05) : 525 - 528
  • [36] VITAMIN PLASMA-LEVELS IN LONG-TERM ENTERAL FEEDING PATIENTS
    BERNER, Y
    MORSE, R
    FRANK, O
    BAKER, H
    SHIKE, M
    CLINICAL RESEARCH, 1988, 36 (03): : A754 - A754
  • [37] VITAMIN PLASMA-LEVELS IN LONG-TERM ENTERAL FEEDING PATIENTS
    BERNER, Y
    MORSE, R
    FRANK, O
    BAKER, H
    SHIKE, M
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1988, 47 (04): : 769 - 769
  • [38] Hepatic steatosis as measured by the computed attenuation parameter predicts fibrosis in long-term methotrexate use
    Tomaszewski, Marcel
    Dahiya, Monica
    Mohajerani, Seyed Amir
    Punja, Hanaa
    Ko, Hin Hin
    Sun, Muxin
    Ramji, Alnoor
    CANADIAN LIVER JOURNAL, 2021, 4 (04): : 370 - 380
  • [39] HEPATIC STEATOSIS DECREASES WITH ADVANCING HEPATIC FIBROSIS: FINDINGS FROM THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS TRIAL (HALT-C)
    Lok, Anna S. F.
    Everhart, James E.
    Chung, Raymond T.
    Kim, Hae-Young
    Everson, Gregory T.
    Hoefs, John C.
    Greenson, Joel K. K.
    HEPATOLOGY, 2008, 48 (04) : 1101A - 1101A
  • [40] Hepatic steatosis development as a long-term complication among testicular germ cell tumor survivors
    Akkus, Erman
    Karaosmanoglu, Ali Devrim
    Gulpinar, Basak
    Suer, Evren
    Urun, Yuksel
    FUTURE ONCOLOGY, 2025, 21 (08) : 983 - 990